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Changing route: aerosol vaccine against tuberculosis
Mycobacterium tuberculosis infects a third of the world’s 
population every year, causing 8·6 million new cases 
and 1·3 million deaths annually.1 BCG, a live-attenuated 
bacterial vaccine developed in the 1920s, is still used 
to vaccinate most children worldwide. Although BCG 
protects infants from severe disseminated disease, 
it cannot prevent infection. Especially in developing 
countries, pulmonary tuberculosis can develop mostly 
during adolescence, and has a high mortality rate 
in patients who are co-infected with HIV. So far, the 
development of vaccines that outperform BCG has 
been diﬃ  cult. 
Recently, 12 new vaccines entered clinical trials as 
part of a global eﬀ ort led by Aeras.2 Since most children 
worldwide are vaccinated with BCG at birth, vaccine 
development eﬀ orts so far have mainly focused on two 
goals: improvement of primary vaccination by replacing 
BCG with engineered live-attenuated bacterial strains 
deriving from BCG or M tuberculosis, and boosting of BCG-
induced immunity with M tuberculosis protein antigens 
delivered in the presence of adjuvants or with viral vectors 
expressing the same antigens.3 One of the most popular 
antigens is the tuberculosis antigen 85A (Ag85A), 
which was ﬁ rst described in 19654 and is present in large 
quantities in culture supernatants of M tuberculosis. This 
antigen induces protective immune responses in mice5 
and has been used extensively to boost the immune 
response elicited by BCG priming. MVA85A is modiﬁ ed 
vaccinia virus Ankara (MVA)—a live-attenuated poxvirus 
vector—that expresses Ag85A. The vaccine candidate was 
developed by an EU-funded consortium (TBVAC) to boost 
pre-existing immunity induced by BCG vaccination.6 
In studies in animals and human beings, this prime–
boost regimen has been shown to be safe and to induce 
strong and polyfunctional CD4+ T-cell responses.6 When 
challenged with M tuberculosis, BCG-primed MVA85A-
boosted animals showed a modest increase in protection 
compared with those vaccinated with BCG alone.6 
However, when intradermally administered MVA85A 
vaccine was tested in a phase 2b eﬃ  cacy trial in South 
Africa involving almost 3000 infants 4–6 months of age7 
the vaccine was conﬁ rmed to be safe, but did not show 
any increase in protection from infection compared 
with the placebo control. In a recent trial in which adult 
volunteers were challenged with BCG vaccination 
MVA85A did not increase the protection elicited by BCG 
immunisation alone.8
The results published so far conﬁ rm that although 
intradermal immunisation with MVA85A in human 
beings induces the expected Th1 and interferon-γ 
responses, it does not increase the protection induced 
by BCG vaccination. The question remains of whether 
the 85A antigen itself is able to induce any protection 
in people, or whether the type of immune response 
induced by intradermal immunisation is appropriate for 
protection. Since several animal models in mice and non-
human primates have shown that intranasal or aerosol-
delivered Ag85A induces better immunity and protection 
than does intradermal immunisation,5,9 the next logical 
step was to test in human beings whether delivery of 
Published Online
August 21, 2014
http://dx.doi.org/10.1016/
S1473-3099(14)70886-2
See Articles page 939
 A
 D
ow
se
tt
, P
ub
lic
 H
ea
lth
 E
ng
la
nd
/S
cie
nc
e 
Ph
ot
o 
Li
br
ar
y
Comment
902 www.thelancet.com/infection   Vol 14   October 2014
The most feared consequence of infection with Myco-
bacterium tuberculosis in infants and young children 
is tuberculous meningitis. In the 1930s, researchers 
established that infants and young children are particularly 
susceptible to tuberculous meningitis, and that it is the 
major cause of tuberculosis-related childhood death.1,2 
The numbers of deaths due to tuberculous meningitis 
worldwide each year are unknown because of diﬃ  culties in 
diagnosis and under-reporting of tuberculosis in children, 
especially when infection causes early death. However, 
tuberculous meningitis is probably a major contributor to 
the estimated 200 or more child deaths every day due to 
tuberculosis worldwide.3 Furthermore, as other common 
causes of meningitis in infants and children become less 
common with the rollout of eﬀ ective bacterial conjugate 
vaccines, M tuberculosis becomes relatively more important 
as a preventable and treatable pathogen causing death 
and disability due to bacterial meningitis in children.4–6
In a systematic review and meta-analysis in The Lancet 
Infectious Diseases, Silvia Chiang and colleagues7 highlight 
the catastrophic consequences of tuberculous meningitis 
in children. Their review included 1636 children 
diagnosed with and treated for tuber culous meningitis 
from ten countries, with reported outcomes spanning ﬁ ve 
decades. Overall, a ﬁ fth of children died during treatment 
(risk 19·3%, 95% CI 14·0–26·1) and half of survivors had 
neurological sequelae (risk 53·9%, 95% CI 42·6–64·9), 
with more advanced disease at presentation associated 
Death and disability: the outcomes of tuberculous meningitis
MVA85A by aerosol, through the use of a nebuliser, would 
improve immunity in the lungs, which are the portal of 
entry for M tuberculosis into the body. 
The Article by Imman Satti and colleagues in The Lancet 
Infectious Diseases reports the ﬁ rst in-human trial of 
MVA85A delivered by aerosol.10 The authors describe a 
double-blind phase 1 clinical trial comparing the safety 
and immunogenicity of MVA85A delivered intradermally 
or by aerosol in healthy adults from the UK who had 
previously been vaccinated with BCG. Although the 
trial had only 12 volunteers in each group, this was 
suﬃ  cient to show that the vaccine delivered by aerosol 
was safe and elicited an immune response in the lungs 
that was superior to that induced by the intradermally 
administered MVA85A. Broncoalveolar lavages (BAL) 
showed increased frequencies of CD4+ T cells speciﬁ c 
for Ag85A that produced interferon-γ, tumour necrosis 
factor (TNF)α, interleukin 2, and interleukin 17, and had 
an increased number of CD4+ T cells simultaneously 
making interferon-γ, TNFα, interleukin 2, and interleukin 
17—a response that is known to be important in the 
control of mycobacterial infection. 
Whether or not the increased local immunity in the 
lungs from the aerosol delivery of MVA85A is going to be 
able to increase the level of protection from tuberculosis 
is still an outstanding question. However, the authors will 
be able to use the BCG challenge model that they recently 
described8 to address this issue. Finally, 50 years after its 
discovery, we might at last be able to answer the question 
of whether the immunity induced by Ag85A is of any use 
to protect people from tuberculosis. 
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